The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.

Over-expression of the proto-oncogene Akt/PKB has been demonstrated in some neuroendocrine tumor models. Akt may activate downstream proteins such as mTOR and p70S6K, inducing tumor proliferation. The rapamycin-derivative RAD001, everolimus, interacts with this pathway by antagonizing mTOR, but its...

Full description

Bibliographic Details
Main Authors:	Grozinsky-Glasberg, S, Rubinfeld, H, Nordenberg, Y, Gorshtein, A, Praiss, M, Kendler, E, Feinmesser, R, Grossman, AB, Shimon, I
Format:	Journal article
Language:	English
Published:	2010

Similar Items

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
by: Grozinsky-Glasberg, S, et al.
Published: (2009)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
by: Grozinsky-Glasberg, S, et al.
Published: (2011)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
by: Druce, M, et al.
Published: (2012)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
by: Druce, M, et al.
Published: (2012)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
by: Druce, MR, et al.
Published: (2009)

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma
by: Druce, M, et al.
Published: (2010)

Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
by: Gueorguiev, M, et al.
Published: (2010)

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
by: Jonas Dietger, et al.
Published: (2009-05-01)

Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3)
by: Chambers, J, et al.
Published: (2010)

RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth.
by: Beat Nyfeler, et al.
Published: (2012-01-01)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
by: Micol Silic-Benussi, et al.
Published: (2023-03-01)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro
by: Eman Awad, et al.
Published: (2017-12-01)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
by: Yim K-L
Published: (2012-07-01)

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1
by: Heba Alshaker, et al.
Published: (2017-06-01)

Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR).
by: Rosa H Jimenez, et al.
Published: (2010-02-01)

The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
by: Orit Uziel, et al.
Published: (2014-12-01)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
by: Michael K Kiessling, et al.
Published: (2016-01-01)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
by: Gigin Lin, et al.
Published: (2018-08-01)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
by: Saira Justin, et al.
Published: (2020-06-01)

Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
by: Gennatas Constantine, et al.
Published: (2012-09-01)

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
by: Keiko Shoji, et al.
Published: (2012-01-01)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
by: James T. Murray, et al.
Published: (2018-05-01)

Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
by: Marcus Bergström, et al.
Published: (2019-12-01)

IGF-1 influences Everolimus activity in medullary thyroid carcinoma
by: Erica eGentilin, et al.
Published: (2015-05-01)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
by: Mathis Wehming, et al.
Published: (2023-02-01)

mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death.
by: Rana Baraz, et al.
Published: (2014-01-01)

Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
by: Michael Wong
Published: (2014-04-01)

Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells
by: Dai ZJ, et al.
Published: (2013-03-01)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
by: Christian Schneeweis, et al.
Published: (2022-04-01)

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
by: Wei Zhao, et al.
Published: (2023-06-01)

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
by: Belinda Seto
Published: (2012-12-01)

Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system
by: Jing eJiang, et al.
Published: (2013-08-01)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
by: Federica Mangili, et al.
Published: (2022-06-01)

The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid Models
by: Adi Knigin, et al.
Published: (2021-12-01)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
by: Chan, H, et al.
Published: (2010)

Rapamycin directly activates lysosomal mucolipin TRP channels independent of mTOR.
by: Xiaoli Zhang, et al.
Published: (2019-05-01)

Structure of the human mTOR Complex I and its implications for rapamycin inhibition
by: Yip, Calvin K., et al.
Published: (2012)